Untitled - The Canadian Association of Gastroenterology

Le foie 743
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for
chronic hepatitis C virus infection. N Engl J Med 2002; 347(13):975-982.
Geller SA. Hepatitis B and hepatitis C. Clin Liver Dis 2002; 6(2):317-334.
Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppresion of hepatitis B e
antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology
2003; 37:756-763.
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment
and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
Lok AS, Lai CL, Leung N, et al. Long term safety of lamivudine treatment in patients
with chronic hepatitis B. Gastroenterology 2003; 125:1714-1722.
Management of Viral Hepatitis: A Canadian Consensus Conference 2003/2004. Online
at www.hepatology.ca.
Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis
B e antigen positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
Section 8 Hépatopathie alcoolique
Akriviadis E, Botlar R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline
improves short-term survival in severe acute alcoholic hepatitis: a double-blind
placebo-controlled trial. Gastroenterology 2000; 119:1637-1648.
Caldwell SH, Li X, Rourk, RM, Millar A, Sosnowski KM, Sue M, Barritt AS, et al.
Hepatitis C infection by polymerase chain reaction in alcoholics: false positive
ELISA results and the influence of infection on clinical prognostic score. Am J
Gastroenterology 1993; 88:1016-1021.
Mathurin P, Abdelnour M, Ramond MJ, et al. Early change in bilirubin levels is an
important prognostic factor in severe alcoholic hepatitis treated with prednisolone.
Hepatology 2003; 38:1363-1369.
O’Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005; 9:
103-134.
Stewart SF, Day CP. The management of alcoholic liver disease. J Hepatol 2003;
38(Suppl. 1):S2-13.
Section 9 Stéatopathie non alcoolique
American Gastroenterological Association. American Gastroenterological Association
medical position statement: non-alcoholic fatty liver disease. Gastroenterology
2002; 123:1702-1704.
Angulo P. Nonalcoholic fatty liver disease. New Engl J Med 2002; 346(16):1221-1231.
Kichian K, McLean R, Granlich LM, Bailey RJ, Bain VG. Nonalcoholic fatty liver
disease in patients investigated for elevated liver enzymes. Can J Gastroenterol
2003; 17(1):38-42.
Section 10 Hépatopathie médicamenteuse
Beaune PH, Lecoeur S. Immunotoxicology of the liver: adverse reactions to drugs.
J Hepatol 1997; 26(Suppl. 2):37-42.
Erlinger S. Drug-induced cholestasis. J Hepatol 1997; 26(Suppl. 1):1-4.
Farrell GC. Liver disease caused by drugs, anesthetics, and toxins. In: Feldman M,
Friedman LS, Sleisenger MH (eds.). Sleisenger & Fordtran’s gastrointestinal and
liver disease. 7th ed. Toronto: WB Saunders, 2002:1403-1447.
Huet PM, Villeneuve JP, Fenyves D. Drug elimination in chronic liver diseases.
J Hepatol 1997; 26(Suppl. 2):63-72.
Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485.